Skip to main content

PacBio Raises $20.6M through Common Stock Sale in H1 2014

NEW YORK (GenomeWeb) – Pacific Biosciences raised $20.6 million in net proceeds through the sale of 3 million shares of its common stock during the first half of 2014, the company disclosed in its Form 10-Q filed with the US Securities and Exchange Commission on Monday.

PacBio said it sold the stock at an average price of $7.12 per share in an at-the-market offering, a type of offering in which shares are offered at the prevailing market prices. The firm added that its current at-the-market offering program has about $17.9 million of common shares available for future sales.

PacBio recently reported that its second quarter revenues jumped 89 percent year over year to $11.4 million. As of June 30, it had $105 million in cash and investments.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.